It’s common to hear that some doctors prescribe insulin when they treat their patients with type 2 diabetes. The problem with adding more insulin to insulin-resistant diabetics is similar to adding more gasoline to a fire. Insulin resistance is not due to a lack of insulin. It’s actually a glycobiology problem—insulin cell receptors are not built correctly on the cell. In type 2 diabetes, the pancreas keeps generating more and more insulin. It is the only way the pancreas has to get the cell’s attention. When insulin correctly binds to the cell, the cell removes excess glucose from the bloodstream. So, insulin resistant type 2 diabetes doesn’t get better with the doctor’s approach because the problem is not more insulin. The problem is at the cell. The cell-surface, sugar structures on the cell membrane are missing glycans which are not allowing the hormone insulin to dock properly at the receptor site. If insulin cannot connect at the glycoprotein receptor, then communication does not take place across the cell membrane. The message to open the door of the cell and absorb glucose from the blood is never heard so the cell doesn’t respond.
The problem discussed above gets much worse when doctors use genetically modified (GMO) insulin. Researchers documented something they are calling double diabetes. What this means is that if someone is taking GMO insulin for type 2, insulin resistant diabetes, they can suddenly develop type 1 diabetes which is the autoimmune version! A two-for-one special—two diabetic conditions when there was only one! Researchers suspect it has something to do with the new genetically engineered (GE) recombinant insulin preparations created by the GE industry.
Similar to how the synthetic version of thyroid hormone replaced the natural pig (porcine) desiccated thyroid hormone, the GE industry has managed to replace the porcine-sourced insulin and drive it from the market. However, GMO synthetics are never tested like normal drugs are. As we teach in our classes, creating correct biological structures like glycoproteins around cell membranes dictates how well they function. Structure is function! GMO insulin is not structurally equivalent to human insulin. Small amino acid and/or sugar substitutions on these glycoproteins can significantly alter their function. Researchers stated “even point amino acid substitutions, which are routinely utilized in the development of insulin analogs, can cause different ionic interactions, hydrogen bonding, hydrophobic packing, and Van der Waals forces which can give rise to markedly different spatial folding patterns.” These differences result in miscommunication and can lead to disease within the body. (Žáková, L. et al. (2014). Human insulin analogues modified at the B26 site reveal a hormone conformation that is undetected in the receptor complex. Acta Crystallographica Section D-Biological Crystallography Journal, 70(Pt 10), 2765-2774.)
“All chemical modifications of the insulin molecule, including elongation with two arginine residues at the C terminus of the B-chain (insulin glargine), and acylation of the hormone with a fatty acid either directly (insulin detemir) or indirectly (insulin degludec) added to the B-chain, can alter the effects of these long-acting insulin analogues on such parameters as glucose transport to cells, stimulation of multiple intracellular pathways and activation of mitogenic processes” (Monnier, L., Colette, C., & Owens, D. (2014). Acylated-based long-acting insulin analogues: Is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes. Diabetes & Metabolism, 40(6), 483-484.)
An inappropriate protein folding pattern could result in synthetic, GE insulin being tagged as a foreign entity. This triggers an immune response and creates inflammation. The synthetic insulin is unable to assume the same glycoprotein structure as the more natural, porcine version. This results in GE insulin being unable to perform the life-sustaining functions we expect from insulin and potentially creates an autoimmune response like type 1 diabetes. These are the types of toxicity problems that seem to always rear their ugly heads in a GE industry that never conducts sufficient animal or human trials before bringing their products to market.
REGISTER before Early Bird Pricing ends on Sept 15!
Our most popular class,
A Wellness Journey
is available two ways!
Click below to order:
- CONSUMER AWARENESS GUIDE
For Active Participants of the GRM:
If you are interested in participating in the GRM, please contact us at firstname.lastname@example.org